Singh, Akhand Pratap; Singh, Rachna; Verma, Sumit Singh; Rai, Vipin; Kaschula, Catherine H.; Maiti, Pralay; Gupta, Subash Chandra published the artcile< Health benefits of resveratrol: Evidence from clinical studies>, SDS of cas: 501-36-0 , the main research area is review resveratrol dietary supplement; chronic diseases; clinical trial; nutraceutical; pharmacokinetics; resveratrol.
A review. Resveratrol is a polyphenolic nutraceutical that exhibits pleiotropic activities in human subjects. The efficacy, safety, and pharmacokinetics of resveratrol have been documented in over 244 clin. trials, with an addnl. 27 clin. trials currently ongoing. Resveretrol is reported to potentially improve the therapeutic outcome in patients suffering from diabetes mellitus, obesity, colorectal cancer, breast cancer, multiple myeloma, metabolic syndrome, hypertension, Alzheimer’s disease, stroke, cardiovascular diseases, kidney diseases, inflammatory diseases, and rhinopharyngitis. The polyphenol is reported to be safe at doses up to 5 g/d, when used either alone or as a combination therapy. The mol. basis for the pleiotropic activities of resveratrol are based on its ability to modulate multiple cell signaling mols. such as cytokines, caspases, matrix metalloproteinases, Wnt, nuclear factor-κB, Notch, 5′-AMP-activated protein kinase, intercellular adhesion mol., vascular cell adhesion mol., sirtuin type 1, peroxisome proliferator-activated receptor-γ coactivator 1α, insulin-like growth factor 1, insulin-like growth factor-binding protein 3, Ras association domain family 1α, pAkt, vascular endothelial growth factor, cyclooxygenase 2, nuclear factor erythroid 2 like 2, and Kelch-like ECH-associated protein 1. Although the clin. utility of resveratrol is well documented, the rapid metabolism and poor bioavailability have limited its therapeutic use. In this regard, the recently produced micronized resveratrol formulation called SRT501, shows promise. This review discusses the currently available clin. data on resveratrol in the prevention, management, and treatment of various diseases and disorders. Based on the current evidence, the potential utility of this mol. in the clinic is discussed.
Medicinal Research Reviews published new progress about Alzheimer disease. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, SDS of cas: 501-36-0 .
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts